Imitrex Injection (Sumatriptan Succinate Injection) - Drug Interactions, Contraindications, Overdosage, etc

DRUG INTERACTIONS

IMITREX INJECTION drug label information in our database does not contain a dedicated section on drug interactions. Please check subsections of WARNINGS AND PRECAUTIONS as well as other sources.

OVERDOSAGE

Patients (n = 269) have received single injections of 8 to 12 mg without significant adverse effects. Volunteers (n = 47) have received single subcutaneous doses of up to 16 mg without serious adverse events.

No gross overdoses in clinical practice have been reported. Coronary vasospasm was observed after intravenous administration of IMITREX Injection (see CONTRAINDICATIONS). Overdoses would be expected from animal data (dogs at 0.1 g/kg, rats at 2 g/kg) to possibly cause convulsions, tremor, inactivity, erythema of the extremities, reduced respiratory rate, cyanosis, ataxia, mydriasis, injection site reactions (desquamation, hair loss, and scab formation), and paralysis. The half-life of elimination of sumatriptan is about 2 hours (see CLINICAL PHARMACOLOGY), and therefore monitoring of patients after overdose with IMITREX Injection should continue while symptoms or signs persist, and for at least 10 hours.

It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentrations of sumatriptan.

CONTRAINDICATIONS

IMITREX Injection should not be given intravenously because of its potential to cause coronary vasospasm.

IMITREX Injection should not be given to patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes. In addition, patients with other significant underlying cardiovascular diseases should not receive IMITREX Injection. Ischemic cardiac syndromes include, but are not limited to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina such as the Prinzmetal variant), all forms of myocardial infarction, and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks. Peripheral vascular disease includes, but is not limited to, ischemic bowel disease (see WARNINGS).

Because IMITREX Injection may increase blood pressure, it should not be given to patients with uncontrolled hypertension.

IMITREX Injection and any ergotamine-containing or ergot-type medication (like dihydroergotamine or methysergide) should not be used within 24 hours of each other, nor should IMITREX Injection and another 5-HT₁ agonist.

IMITREX Injection should not be administered to patients with hemiplegic or basilar migraine.

IMITREX Injection is contraindicated in patients with hypersensitivity to sumatriptan or any of its components.

IMITREX Injection is contraindicated in patients with severe hepatic impairment.